More News

Weekly Poll of MDs and ODs, US Only, November 2026
Weekly Poll of MDs and ODs, US Only, November 2026
November 2026 Ophthalmic News Briefs
November 2026 Ophthalmic News Briefs
Volk Optical announced Oct. 7 the launch of ClearField Pro, a new lens for retinal examination and laser indirect ophthalmoscopy. The lens’ coating provides up to 77 percent less reflectivity, Volk...
US FDA Orders GLP-1 Makers to Warn of Potential for Vision Loss
US FDA Orders GLP-1 Makers to Warn of Potential for Vision Loss
The US FDA announced Nov. 9 that it would require safety labeling changes for the entire class of glucagon-like peptide-1 (GLP-1) receptor agonists, including the popular weight loss drugs Wegovy a...
Chinese Regulators Approve PT Lunana Phakic IOL from Zeiss for Myopia
Chinese Regulators Approve PT Lunana Phakic IOL from Zeiss for Myopia
German company Carl Zeiss Meditec announced on Nov. 9 that China’s National Medical Products Administration (NMPA) had approved the company’s PT Lunana phakic intraocular lens (IOL). The lens was s...
Q3-2026 Ophthalmic Revenue Roundup for Alcon, Harrow, STAAR Surgical, ANI, and Sight Sciences
Q3-2026 Ophthalmic Revenue Roundup for Alcon, Harrow, STAAR Surgical, ANI, and Sight Sciences
Alcon reported Nov. 10 that its Q3-2026 net sales were $2.7 billion, a 5 percent increase (+5 percent cc) over $2.6 billion in Q3-2025. Surgical net sales for implantables, consumables, and equipme...
Santen Gains Korean Marketing Approval for Ryjusea (Atropine) for Myopia
Santen Gains Korean Marketing Approval for Ryjusea (Atropine) for Myopia
Japan’s Santen Pharmaceutical announced Nov. 2 that it had gained marketing approval in South Korea for preservative-free Ryjusea low-dose atropine drops to slow the progression of pediatric myopia...
Alberta Is First Province in Canada to Authorize Optometric Surgery
Alberta Is First Province in Canada to Authorize Optometric Surgery
Alberta on Nov. 1 became the first province in Canada to allow qualified optometrists with additional training to perform certain minor surgical and laser procedures in their offices. Under the exp...
Tenpoint Launches Telehealth Prescribing Option for Yuvezzi Presbyopia Drops
Tenpoint Launches Telehealth Prescribing Option for Yuvezzi Presbyopia Drops
Tenpoint Therapeutics announced Nov. 9 that it was making its presbyopia drop, Yuvezzi, available online through a telehealth platform at orderyuvezzi.com. Tenpoint said the site offers patients a ...
Emerging Company Imvionix Acquires Rights to Beovu in US, Canada
Emerging Company Imvionix Acquires Rights to Beovu in US, Canada
Imvionix, a privately held emerging retinal pharmaceutical company, announced Nov. 10 that it had acquired exclusive commercial rights to Beovu (brolucizumab-dbll) in the US and Canada from Novarti...
US FDA Grants Orphan Drug Status to Octant’s Oral RP Candidate
US FDA Grants Orphan Drug Status to Octant’s Oral RP Candidate
Octant, of Emeryville, California, announced Oct. 27 that the US FDA had granted orphan drug status to OCT-980, an oral treatment candidate targeting retinitis pigmentosa (RP). Orphan drug designat...
Q3-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Tarsus, RxSight, and Xbrane
Q3-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Tarsus, RxSight, and Xbrane
Regeneron of Tarrytown, New York, reported Oct. 30 that its Q3-2026 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was just under $1.1 billion, a 1 perc...
Harrow Launches HarrowRx Platform, Accessible to Doctors Through EMRs
Harrow Launches HarrowRx Platform, Accessible to Doctors Through EMRs
Nashville, Tennessee-based Harrow reported Nov. 2 that it had launched HarrowRx, allowing eye care providers to prescribe all of Harrow’s branded products within their electronic medical record (EM...
Lenz Announces Plans for Major Layoffs, CEO Switch
Lenz Announces Plans for Major Layoffs, CEO Switch
Lenz Therapeutics, of San Diego, California, announced Oct. 28 a strategic reorganization to reduce projected 2027 annual operating expenses by over 50 percent as it continues to roll out Vizz, its...
US FDA Approves Ranibizumab (Lucentis) Biosimilar from Xbrane
US FDA Approves Ranibizumab (Lucentis) Biosimilar from Xbrane
Sweden’s Xbrane Biopharma announced Oct. 27 that the US FDA had approved its ranibizumab (Lucentis) biosimilar, to be branded Lucamzi in the US. It was approved to treat wet age-related macular deg...
Global Summit for Eye Health Draws Over $1 Billion in Commitments to Fight Avoidable Blindness
Global Summit for Eye Health Draws Over $1 Billion in Commitments to Fight Avoidable Blindness
World leaders, international agencies, and private sector partners met in St. John’s, the capital of Antigua and Barbuda, on Nov. 2 at the Global Summit for Eye Health, an event organized by the In...
Ranibizumab Biosimilar from Accord Gains Positive CHMP Opinion
Ranibizumab Biosimilar from Accord Gains Positive CHMP Opinion
UK-based Accord Healthcare announced Oct. 15 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval for Fovlussea, its proposed biosimil...
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’ ...
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
India’s Appasamy Associates, a portfolio company of Warburg Pincus, reported Oct. 22 that it had acquired German company Ruck, manufacturer of ophthalmic surgical products for both the front and ba...
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz
Bausch + Lomb reported Oct. 28 that its Q3-2026 revenue totaled $1.4 billion, a 7 percent increase (+8 percent cc) from $1.3 billion in Q3-2025. Ophthalmic pharmaceuticals segment revenue was $367 ...
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA
Opus Genetics announced on Oct. 21 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of OPGx-RDH12, a gene therapy ca...
Researchers Develop New Standardized Grading System for MGD
Researchers Develop New Standardized Grading System for MGD
A study published Oct. 6 in Clinical Optometry introduces the Meibomian Gland Composite Score (MGCS)—a standardized grading system that could help clinicians more precisely track meibomian gland dy...
Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment
Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment
Volk Optical announced Oct. 7 the launch of ClearField Pro, a new ophthalmic lens designed for retinal examination and laser indirect ophthalmoscopy. The lens’ advanced coating provides up to 77 pe...
Visara Gains Exclusive Option to Acquire Candidate for Ocular Surface Squamous Neoplasia
Visara Gains Exclusive Option to Acquire Candidate for Ocular Surface Squamous Neoplasia
Visara, the ophthalmology subsidiary of NovaBridge Biosciences, announced Oct. 20 that it had gained an exclusive option to acquire worldwide rights to YOLO Immune’s YOL104-2, a candidate for ocula...
RadiusXR, Topcon Introduce InspirePro Wearable Perimeter
RadiusXR, Topcon Introduce InspirePro Wearable Perimeter
RadiusXR and strategic partner Topcon Healthcare introduced the lightweight, wearable InspirePro perimeter at the American Academy of Ophthalmology’s 2026 meeting, held Oct. 10-12 in New Orleans, L...
Stuart Submits IND Amendment to US FDA for Trial of ST-100 in Corneal Wound Healing
Stuart Submits IND Amendment to US FDA for Trial of ST-100 in Corneal Wound Healing
Stuart Therapeutics announced Oct. 9 that it had submitted an investigational new drug application (IND) amendment to the US FDA to study its lead candidate, ST-100 (vezocolmitide) eye drops, in co...
EMA Grants Orphan Drug Status to BlueRock’s IRD Cell Therapy Candidate
EMA Grants Orphan Drug Status to BlueRock’s IRD Cell Therapy Candidate
Bayer subsidiary BlueRock Therapeutics announced Sept. 30 that its investigational cell therapy, lemiretprocel (OpCT-001), had received orphan drug designation from the European Medicines Agency. T...
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make a...
Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision
Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision
Swiss company Roche reported Oct. 22 that Q3-2026 Vabysmo sales were CHF 1.1 billion ($1.4 billion, converted for Sept. 20, 2026) a 13 percent increase over CHF 996 million in Q3-2025. US Vabysmo s...
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops
Alcon announced Oct. 16 that the US FDA had approved Brytly (apraclonidine 0.125%), a redness relieving eye drop. The company said one drop of Brytly works in one minute and lasts up to 12 hours, o...
Lens-vs.-Laser Debate Heats Up at ESCRS Congress as New Refractive Technologies are Launched
Lens-vs.-Laser Debate Heats Up at ESCRS Congress as New Refractive Technologies are Launched
The long-running debate between laser- and lens-based refractive surgery intensified at the 2026 ESCRS congress in London, where new product launches and packed scientific sessions underscored a ma...
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia
Commercial partners Viatris and Opus Genetics reported Oct. 16 that the US FDA had approved Ryzumvi (phentolamine ophthalmic solution 0.75%) as a treatment for presbyopia. The milestone marks the f...
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...
Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland
Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland
Belite Bio announced Oct. 14 that it had filed for marketing approval for its oral Stargardt treatment candidate, tinlarebant, in three countries—Singapore, the UK, and Switzerland—under those nati...
Haag-Streit and Marco Lombart Launch Octopus 910 Perimeter in the US
Haag-Streit and Marco Lombart Launch Octopus 910 Perimeter in the US
Haag-Streit USA and distributor Marco Lombart reported Oct. 10 that they had launched the Octopus 910 perimeter in the US. A global launch is set for January 2027. The full-field projection perimet...
Futures Forum Highlights Higher Investment Bar, Looks at AI Concerns
Futures Forum Highlights Higher Investment Bar, Looks at AI Concerns
A common theme at the 2026 Ophthalmology Futures European Forum was that capital and innovation remain available, but the bar for both has risen. The forum was held Sept. 10 at Glaziers Hall on the...
Miticides to Treat Dry Eye Climbing Toward $1 Billion in Annual Sales
Miticides to Treat Dry Eye Climbing Toward $1 Billion in Annual Sales
Tarsus Pharmaceuticals is behind the rapid growth of the miticide category of dry-eye related pharmaceuticals in the US. Market Scope expects US sales in the miticide category to soon exceed $1 bil...
Gene Therapy Reclaims Top Spot in Ophthalmic Fundraising
Gene Therapy Reclaims Top Spot in Ophthalmic Fundraising
Ophthalmic gene therapy fundraising has reached nearly $1.3 billion in 2026, propelled by major investments in Beacon Therapeutics, Regenxbio, and MeiraGTx. Beacon closed a Series C round in Januar...
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over
Bausch + Lomb announced Oct. 12 that CEO Brent Saunders would leave the company immediately, with chairman Thomas Appio taking over as interim CEO. Appio also is CEO of Bausch Health. Saunders had ...
Rayner Launches RayOne Galaxy IOL in US after Receiving FDA Approval
Rayner Launches RayOne Galaxy IOL in US after Receiving FDA Approval
UK-based Rayner announced Sept. 24 that its RayOne Galaxy and RayOne Galaxy Toric IOLs were commercially available in the US after the lenses gained FDA approval. The Galaxy is the first-ever spira...
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make a...
FDA Panel Meeting for Sydnexis’ Rejected Myopia Drop Set for Oct. 30
FDA Panel Meeting for Sydnexis’ Rejected Myopia Drop Set for Oct. 30
Sydnexis reported Sept. 24 that the US FDA had set Oct. 30 as the date for an advisory committee and open public hearing to review the new drug application (NDA) for SYD-101, an atropine eye drop c...
Select US FDA Approvals and Clearances in September 2026
Select US FDA Approvals and Clearances in September 2026
The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in September 2026, according to the agency’s database. Kowa received clearance for its updated FM...
Aldeyra to File Formal Dispute with US FDA over Reproxalap Rejection
Aldeyra to File Formal Dispute with US FDA over Reproxalap Rejection
Aldeyra Therapeutics reported Sept. 29 that it would submit a formal dispute resolution request with the US FDA over the rejection of reproxalap, a topical treatment candidate for dry eye disease. ...
PDUFA Dates for Ophthalmic Drug Candidates, October 2026
PDUFA Dates for Ophthalmic Drug Candidates, October 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops
Alcon announced Oct. 16 that the US FDA had approved Brytly (apraclonidine 0.125%), a redness relieving eye drop. The company said one drop of Brytly works in one minute and lasts up to 12 hours, o...
US FDA Approves Genentech’s Enspryng, the First Subcutaneous Treatment for TED
US FDA Approves Genentech’s Enspryng, the First Subcutaneous Treatment for TED
Genentech and its parent, Roche, announced Oct. 16 that the US FDA had approved Enspryng (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED). It’s the first at-home, subc...
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia
Commercial partners Viatris and Opus Genetics reported Oct. 16 that the US FDA had approved Ryzumvi (phentolamine ophthalmic solution 0.75%) as a treatment for presbyopia. The milestone marks the f...
Next-Generation Glaucoma Technologies May Hasten Shift Toward Earlier Intervention
Next-Generation Glaucoma Technologies May Hasten Shift Toward Earlier Intervention
Glaucoma treatment is entering a new phase as developers of lasers and surgical devices pursue technologies designed to deliver greater reduction of intraocular pressure (IOP) while maintaining the...
City Therapeutics Leads Latest Fundraising with $230 Million IPO
City Therapeutics Leads Latest Fundraising with $230 Million IPO
City Therapeutics led recent ophthalmic fundraising efforts with a $230 million upsized initial public offering to advance its candidates for GA and Stargardt. Financing announced in the past four ...
Glaukos Licenses Tri-specific Retinal  Candidate from RevOpsis
Glaukos Licenses Tri-specific Retinal Candidate from RevOpsis
Glaukos announced Oct. 8 that it had licensed from RevOpsis Therapeutics exclusive rights to RO-104, a novel tri-specific biologic candidate targeting wet age-related macular degeneration, diabetic...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.